Express Pharma
Home  »  Latest Updates  »  Mylan seeks EMA approval for two biosimilars

Mylan seeks EMA approval for two biosimilars

11

According to Biocon, it has completed the corrective and preventive actions (CAPAs), including the facility modifications, in response to the audit observations

Biocon said that its partner Mylan has re-submitted marketing authorisation applications with the European Medicines Agency for two biosimilars Trastuzumab and Pegfilgrastim.

“Biocon’s partner Mylan has re-submitted the marketing authorisation applications (MAAs) for our proposed biosimilar Trastuzumab and Pegfilgrastim with the European drug regulator European Medicines Agency (EMA) as per administrative protocol,” the company said in a regulatory filing today.

The company said this follows earlier withdrawal of both the applications in response to observations made by the European regulator.

“Biocon has completed the corrective and preventive actions (CAPAs), including the facility modifications, in response to the audit observations and expects these to be verified during re-inspection,” it added.

Comments are closed.